Opthea (ASX:OPT) says it has finalised the protocol study designs and key start-up activities in readiness for the initiation of the phase three ShORe and COAST pivotal clinical trials of OPT-302 in wet age-related macular degeneration. …
Opthea confirms plans and protocols for late-stage OPT-302 studies
February 24, 2021 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 5 September
September 5, 2025 - - Podcast -
Novartis ANZ appoints Marco Muscardo as ad-interim Country PresidentÂ
September 4, 2025 - - Latest News -
Australian industry looks to the UK as likely lesson for US 'Most Favored Nation'
September 4, 2025 - - Latest News -
Every new working group and every consultation squeezes more life out of reform, like a lemon wrung to its rind
September 4, 2025 - - Latest News -
The latest HTA Review report is a Dickensian tribute to policymaking and reform
September 3, 2025 - - Latest News -
Stakeholders could be mistaken for thinking the process is the point
September 3, 2025 - - Latest News -
Regulate the regulators - Why NDIS audit fees are failing providers and participants
September 3, 2025 - - Latest News